Evidence map›Paper›PMID 26945387›Full record

ArticleMedicine2016

The Value of PET/CT in Detecting Bone Marrow Involvement in Patients With Follicular Lymphoma.

Chava Perry, Hedva Lerman, Erel Joffe, Nadav Sarid, Odelia Amit, Irit Avivi, Mikhail Kesler, Jonathan Ben-Ezra, Einat Even-Sapir, Yair Herishanu

Open access · goldAbstract read
In one paragraph

Article in Medicine, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
16citing papers in PubMed, 1 pooled it
3.9field-weighted citation impact, top 7% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

16 citing papers in PubMed, 1 synthesis or guideline pooled it, 36 citations in OpenAlex.

  1. Pooled it
  2. Trial
  3. Article
  4. The Role of [Cancers · 2025
    Article
  5. Article
  6. Diagnostic value of baselineScientific reports · 2021
    Article
  7. Utility ofThe Indian journal of medical research · 2021
    Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Review
  14. European journal of nuclear medicine and molecular imaging · 2017
    Article
  15. FDG-PET Scan: a new Paradigm for Follicular Lymphoma Management.Mediterranean journal of hematology and infectious diseases · 2017
    Review
  16. Diagnostic Accuracy ofPakistan journal of medical sciences
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 1 institution in 1 country.

Chava PerryFrom the Department of Hematology (CP, EJ, NS, OA, IA, YH); Department of Nuclear Medicine (HL, MK, EES); Department of Pathology, Tel Aviv Sourasky Medical Center (B-E); and Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel (B-E, EES, IA, YH).
Hedva Lerman
Erel Joffe
Nadav Sarid
Odelia Amit
Irit Avivi
Mikhail Kesler
Jonathan Ben-Ezra
Einat Even-Sapir
Yair Herishanu
Tel Aviv Sourasky Medical Center · IL

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Follicular lymphoma (FL) is the 2nd most common type of lymphoma diagnosed in the Western World. Bone marrow (BM) involvement is an adverse prognostic factor in FL, routinely assessed by an arbitrary biopsy of the iliac crest. This study was aimed to investigate the role of positron emission tomography/computed tomography (PET/CT) in identifying BM involvement by FL. In this retrospective, single-center study we reviewed the records of consecutive patients with FL at diagnosis or relapse who underwent staging/restaging workup visual assessment of BM uptake was categorized as either normal, diffusely increased, or focally increased. Quantitative BM fluorine-18-fluro-deoxyglucose (FDG) uptake was measured using mean standardized uptake value (BM-SUVmean). The diagnosis of BM involvement was based on either BM histological findings or disappearance of increased uptake at end-treatment PET/CT in patients who responded to treatment. Sixty eight cases with FL were included. Sixteen (23.5%) had BM involvement, 13 (19.1%) had a biopsy proven involvement, and 3 (4.4%) had a negative BM biopsy, but increased medullary uptake that normalized post-treatment. BM FDG uptake in these patients was diffuse in 8 (50%) and focal in 8 (50%). Focal increased uptake was indicative of BM involvement; however, diffuse uptake was associated with 17 false positive cases (32.7%). Overall, visual assessment of BM involvement had a negative predictive value (NPV) of 100% and a positive predictive value (PPV) of 48.5%. On a quantitative assessment, BM-SUVmean was significantly higher in patients with BM involvement (SUVmean of 3.7 [1.7-6] vs 1.4 [0.4-2.65], P < 0.001). On receiver operator curve (ROC) analysis, BM-SUVmean > 2.7 had a PPV of 100% for BM involvement (sensitivity of 68%), while BM-SUVmean < 1.7 had an NPV of 100% (specificity of 73%). Visual assessment of PET/CT is appropriate for ruling out BM involvement by FL. Although focal increased uptake indicates marrow involvement, diffuse uptake is nonspecific. SUV measurement improves PET/CT diagnostic accuracy, identifying additional 19% of patients with BM involvement that would have been otherwise missed.

Indexed as

Positron-Emission TomographyTomography, X-Ray ComputedBiopsyBone Marrow NeoplasmsFalse Positive ReactionsFemaleFluorodeoxyglucose F18HumansLymphoma, FollicularMaleMiddle AgedPredictive Value of TestsRetrospective StudiesROC CurveFluorodeoxyglucose F18

Identifiers

PMID26945387
PMCPMC4782871
OpenAlexW2330058926

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.